Ryan McDonald

Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.


Cervical Cancer Survivor Donates Embryos to Fellow Survivor to Help Fulfill Dream of Motherhood

August 25, 2022

Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.

First Patient Receives Treatment With Investigational CAR-T Cell Therapy-Opdivo Combo for Hodgkin Lymphoma

August 18, 2022

A representative of the company developing the investigational CAR-T cell therapy noted that they hypothesize that the combination “has the potential to further enhance efficacy and provide patients with a chemotherapy-sparing, second-line treatment option.”

Patient With Metastatic Breast Cancer Recalls Witness of Data Leading to Enhertu Approval in HER2-Low Disease

August 17, 2022

A patient with metastatic breast cancer recalls the emotional experience of being among the thousands of attendees who gave a standing ovation in an auditorium in Chicago when the results of the phase 3 DESTINY-Breast04 trial — which recently led to the FDA approval of Enhertu in HER2-low disease — were presented at the 2022 ASCO Annual Meeting.

FDA Grants Priority Review to Investigational Drug for a Subtype of Advanced or Metastatic Breast Cancer

August 11, 2022

The FDA’s decision to grant the investigational drug elacestrant a priority review for patients with ER-positive, HER2-negative advanced or metastatic breast cancer was based on data that showed the treatment bested standard-of-care in terms of improving survival.

Keytruda-Lenvima Combo Fails to Top Lenvima Alone in Patients With Unresectable Liver Cancer

August 09, 2022

Treatment with Keytruda plus Lenvima did not best Lenvima alone as a first-line treatment option for a group of patients with liver cancer that could not be treated with surgery, according to recently announced study results from a phase 3 clinical trial.

Investigational Drug-Libtayo Combo Demonstrates Clinical Activity in Metastatic Prostate Cancer

August 08, 2022

Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.

Onivyde Fails to Improve Survival Over Chemotherapy in Second-Line Small Cell Lung Cancer

August 05, 2022

Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.

Standard of Care Chemotherapy Treatment Bests Immunotherapy-Based Regimens in Advanced Liver Cancer

July 28, 2022

Treatment with Opdivo plus standard of care chemotherapy followed by maintenance Opdivo or Opdivo plus Yervoy failed to elicit survival benefits compared with standard of care chemotherapy alone in patients with previously untreated advanced biliary cancer, which is a rare form of liver cancer.

FDA to Expedite Review of Novel Drug in Subset of Metastatic Breast Cancer

July 21, 2022

Investigators are analyzing the novel drug, OP-1250, both as a single-agent treatment option and in combination with Ibrance in patients with recurrent, locally advanced or metastatic ER-positive/HER2-negative breast cancer.